Richiedi info sul prodotto
Estimated delivery: 2-5 working days
Information on returns and shipments
Payment methods
Drug for the symptomatic treatment of fever and mild to moderate pain.
Decaflu fever and pain strawberry-flavored oral suspension is a symptomatic treatment of fever and mild to moderate pain.
Each ml of oral suspension contains: Active ingredient: ibuprofen 20 mg. Excipients: maltitol syrup 753.30 mg. For the full list of excipients, see section 6.1.
Citric acid monohydrate, sodium citrate, acesulfame potassium, xanthan gum, sodium benzoate, strawberry flavoring, maltitol syrup, glycerin, purified water.
The daily dose is structured according to the weight and age of the patient. The lowest effective dose should be used for the shortest period necessary to relieve symptoms (see section 4.4). In children aged 3 to 6 months, limit administration to those weighing more than 5.6 kg. Oral administration to infants and children aged 3 months to 12 years should be done using the measuring syringe provided with the product. The graduated scale on the body of the syringe clearly shows the notches for the different dosages; in particular, the 2.5 ml mark corresponds to 50 mg of ibuprofen and the 5 ml mark corresponds to 100 mg of ibuprofen. The daily dose of 20-30 mg/kg of body weight, divided 3 times a day at intervals of 6-8 hours, can be administered according to the following schedule.
| Weight | Age | Single dose in ml | n° Maximum number of administrations/day |
| 5.6 -7 Kg | 3 - 6 months | 2.5 ml | 3 in 24 hours |
| 7 -10 Kg | 6 - 12 months | 2,5 ml | |
| 10 - 15 Kg | 1 - 3 years | 5 ml | |
| 15 - 20 Kg | 4 - 6 years | 7.5 ml (5 ml + 2.5 ml) | |
| 20 - 28 Kg | 7 - 9 years | 10 ml | |
| 28 - 43 Kg | 10 - 12 years | 15 ml |
In case of post-vaccination fever, refer to the dosage indicated above, administering a single dose followed, if necessary, by another dose after 6 hours. Do not administer more than two doses in 24 hours. Consult your doctor if the fever does not decrease. The product is intended for short-term treatments. If use of the medicine is necessary for more than one year, consult your doctor. 3 days in infants and children over 6 months of age and in adolescents, or in case of worsening of symptoms, a doctor must be consulted. In infants aged between 3 and 5 months, a doctor should be consulted if symptoms persist for more than 24 hours or if symptoms worsen.
Instructions for using the dosing syringe
After three days of treatment without appreciable results, consult your doctor. Undesirable effects can be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Masking of symptoms of underlying infections Decaflu Fever and Pain may mask the symptoms of infection, which could delay the initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and in bacterial complications of chickenpox. When Decaflu Fever and Pain is administered for the relief of infection-related fever or pain, monitoring for the infection is recommended. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen. The use of Decaflu Fever and Pain should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to these types of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after using other analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), nasal polyps, or previous episodes of angioedema (see sections 4.2 and 4.8). Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal (see section 4.2). The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcers, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest available dose. Concomitant use of protective agents (e.g., misoprostol or proton pump inhibitors) should be considered for these patients, as well as for patients taking low-dose aspirin or other drugs likely to increase the risk of gastrointestinal events (see section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as aspirin (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients taking Decaflu Fever and Pain, the treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease), as these conditions may be exacerbated (see section 4.8). Serious skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy, with the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in connection with products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of serious skin reactions, such as rash, mucosal lesions, or any other sign of hypersensitivity. Drug reactions with eosinophilia and systemic symptoms (DRESS syndrome) have been observed with unknown frequency (see section 4.8). Caution is advised before initiating treatment in patients with a history of hypertension and/or heart failure, as fluid retention, hypertension, and edema have been reported in association with NSAID therapy. Clinical trial and epidemiological data suggest that use of ibuprofen, particularly at high doses (2400 mg/day) and in long-term treatment, may be associated with a small increased risk of arterial thrombotic events (e.g., myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g., ≤1200 mg/day) are associated with an increased risk of myocardial infarction. In cases of severe poisoning, metabolic acidosis may occur (see section 4.9). Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should be treated with ibuprofen only after careful consideration. Similar consideration should be made before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). The use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, non-steroidal anti-inflammatory drugs requires particular caution:
In dehydrated children and adolescents there is a risk of alteration of renal function. The following precautions are important during prolonged treatment:
Patients with rare hereditary problems of fructose intolerance should not take this medicine. This medicine contains:
Hypersensitivity to ibuprofen or to any of the excipients listed in section 6.1. Children under 3 months of age or weighing less than 5.6 kg.
The following interactions are common: to ibuprofen, acetylsalicylic acid and other analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs):
The undesirable effects observed with ibuprofen are common to other analgesics, antipyretics, and non-steroidal anti-inflammatory drugs.
Hypersensitivity reactions
Rarely: anaphylactoid reactions (urticaria with or without angioedema), dyspnoea (due to laryngeal obstruction or bronchospasm), shock, syndrome characterized by abdominal pain, fever, chills, nausea and vomiting; bronchospasm (see sections 4.3 and 4.4).
Gastrointestinal disorders
The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, particularly in the elderly, may occur (see section 4.4). After administration of Decaflu Fever and Pain, the following have been reported: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. Epigastric pain, heartburn. Gastric disturbances can be reduced by taking the drug with food. Rarely: hepatitis, jaundice, abnormal liver function tests, pancreatitis, duodenitis, esophagitis, hepatorenal syndrome, liver necrosis, liver failure.
Nervous system and sensory disorders
Vertigo, headache, irritability, tinnitus. Rarely: depression, insomnia, difficulty concentrating, emotional lability, somnolence, aseptic meningitis, convulsions, hearing and vision disturbances.
Respiratory, thoracic and mediastinal disorders
Rarely: bronchospasm, dyspnoea, apnoea.
Skin and subcutaneous tissue disorders
Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) (frequency not known), bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare). Skin rashes (including maculopapular), pruritus. Rarely: vesiculobullous eruptions, urticaria, erythema multiforme, alopecia, exfoliative dermatitis, photosensitivity dermatitis. Frequency not known: Acute generalized exanthematous pustulosis (AGEP)
Blood and lymphatic system disorders
Very rarely: neutropenia, agranulocytosis, aplastic anemia, haemolytic anemia (possibly positive Coombs test), thrombocytopenia (with or without purpura), eosinophilia, decreased haemoglobin and haematocrit, pancytopenia.
Metabolism and nutrition disorders
Decreased appetite. Cardiac and vascular disorders: Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. Fluid retention (usually responds promptly to discontinuation of treatment). Very rarely: cerebrovascular accident, hypotension, congestive heart failure in patients with compromised cardiac function, palpitations. Clinical studies and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg/day) and for long-term treatment, may be associated with a modestly increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4).
Renal and urinary disorders
Very rarely: acute renal failure in subjects with pre-existing significantly impaired renal function, papillary necrosis, tubular necrosis, glomerulonephritis, abnormal renal function tests, polyuria, cystitis, haematuria.
Immune system disorders
In patients with pre-existing autoimmune diseases (e.g. systemic lupus erythematosus, connective tissue diseases), single cases of symptoms of aseptic meningitis such as neck tension, headache, nausea, vomiting, fever, disorientation have been reported (see section 4.4). Various Rarely: dry eyes and mouth, gum ulcers, rhinitis.
Symptoms of overdose may occur in children who have taken more than 400 mg/kg. The half-life of the drug in case of overdose is 1.5-3 hours. Symptoms Most patients who accidentally ingest clinically relevant amounts of NSAIDs develop at most nausea, vomiting, epigastric pain, or rarely diarrhea. Tinnitus, headache, and gastrointestinal bleeding are also possible. In case of ingestion of larger quantities, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitation and disorientation or coma, and convulsions. In cases of severe poisoning, metabolic acidosis and prolongation of the prothrombin time (INR) may occur. Renal failure and liver damage may also occur. Asthmatics may experience exacerbation of disease symptoms. Treatment: There is no antidote to ibuprofen. Treatment is symptomatic and consists of appropriate supportive measures. Maintain airway patency and monitor cardiac function and vital signs. Particular attention is paid to blood pressure, acid-base balance, and any gastrointestinal bleeding. In cases of acute overdose, gastric emptying (vomiting or gastric lavage) is more effective the earlier it is performed; administration of alkali and induction of diuresis may also be useful; ingestion of activated charcoal may help reduce drug absorption.
Persons under 12 years of age are unlikely to become pregnant or breastfeed. However, in such circumstances, the following considerations should be taken into account. Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryonic/fetal development. Epidemiological studies suggest an increased risk of miscarriage, cardiac malformation, and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. Additionally, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction that may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect that may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor.
150 ml with measuring syringe.
This product has been on sale since 17/12/2018
In the last 30 days, the product's lowest price was 10,39 €
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
Estimated delivery: 2-5 working days
